id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-E-4403-0005,FDA,FDA-2018-E-4403,"Determination of Regulatory Review Period for Purposes of Patent
Extension; AIMOVIG",Notice,Determinations,2019-12-03T05:00:00Z,2019,12,2019-12-03T05:00:00Z,2020-02-04T04:59:59Z,2020-02-03T02:00:48Z,2019-26081,0,0,09000064841dda28
FDA-2018-E-4403-0004,FDA,FDA-2018-E-4403,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T20:33:15Z,,0,0,090000648411687c
FDA-2018-E-4403-0003,FDA,FDA-2018-E-4403,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-13T04:00:00Z,2019,5,2019-05-13T04:00:00Z,,2019-05-13T17:39:59Z,,0,0,0900006483c71994